What are the appropriate medications for treating new‑onset heart failure with reduced ejection fraction in an African‑American male with impaired renal function, elevated B‑type natriuretic peptide, and an echocardiogram showing ejection fraction of 30‑45%?

Medication Regimen for New-Onset HFrEF in African American Male with CKD Stage 3b

This patient should be initiated on quadruple guideline-directed medical therapy (GDMT) consisting of: (1) an ACE inhibitor or ARB (or ARNI if tolerated), (2) a beta-blocker, (3) a mineralocorticoid receptor antagonist (MRA), and (4) an SGLT2 inhibitor, with the addition of (5) hydralazine-isosorbide dinitrate given his African American race. 1, 2

Step 1: Foundational Quadruple Therapy

The 2022 ACC/AHA/HFSA guidelines emphasize simultaneous or rapid sequential initiation of all four foundational drug classes without waiting to achieve target dosing before starting the next medication 1, 2. This approach reduces mortality by 73% over 2 years compared to no treatment 2.

Renin-Angiotensin System Inhibition

• Start with an ACE inhibitor (e.g., lisinopril 2.5-5 mg daily or enalapril 2.5 mg twice daily) given the renal impairment (eGFR 42)
• ARNI (sacubitril/valsartan) is NOT recommended in this patient because it should not be used when eGFR <30 mL/min/1.73 m², and with eGFR 42, you're approaching this threshold with limited safety margin 3
• The presence of CKD should not preclude RAS inhibitor use, but requires close monitoring for worsening renal function and hyperkalemia 3, 4
• Monitor creatinine and potassium within 1-2 weeks after initiation; accept up to 30% increase in creatinine as this often represents hemodynamic changes rather than true kidney injury 4

Beta-Blocker

• Initiate carvedilol 3.125 mg twice daily OR metoprolol succinate 12.5-25 mg daily 1
• Avoid bisoprolol in this patient as it may accumulate with renal impairment, though all three beta-blockers are generally safe 3
• Titrate to target doses (carvedilol 25-50 mg twice daily, metoprolol succinate 200 mg daily) over 6-12 weeks 2

Mineralocorticoid Receptor Antagonist (MRA)

• Start spironolactone 12.5 mg daily or every other day given the eGFR of 42 3
• MRAs are appropriate when eGFR ≥30 mL/min/1.73 m², but require cautious dosing and monitoring 3
• Critical monitoring: Check potassium and creatinine within 3-7 days, then weekly until stable
• Hold if potassium >5.5 mEq/L; restart at lower dose when potassium <5.0 mEq/L
• Can uptitrate to 25 mg daily if potassium remains <5.0 mEq/L and renal function stable 3

SGLT2 Inhibitor

• Initiate dapagliflozin 10 mg daily OR empagliflozin 10 mg daily 1, 2
• Both are effective with eGFR ≥25 mL/min/1.73 m² (dapagliflozin) or ≥20 mL/min/1.73 m² (empagliflozin) 3
• These agents reduce cardiovascular and renal outcomes even in CKD 3, 4
• Monitor for volume depletion due to osmotic diuretic effect, especially with concurrent loop diuretics

Step 2: Race-Specific Therapy for African Americans

Hydralazine-Isosorbide Dinitrate

This patient qualifies for hydralazine-isosorbide dinitrate based on his African American race, and this should be added to the regimen above 1. The A-HeFT trial demonstrated mortality reduction specifically in African American patients when added to standard therapy including ACE inhibitors, beta-blockers, and MRAs 1.

• Start hydralazine 37.5 mg three times daily + isosorbide dinitrate 20 mg three times daily
• Target doses: hydralazine 75 mg three times daily + isosorbide dinitrate 40 mg three times daily
• This combination is cost-effective with incremental cost per life-year <$60,000 1
• Important caveat: There are insufficient data for concomitant use with ARNI, so if you later transition to ARNI, the benefit of continuing hydralazine-isosorbide dinitrate becomes uncertain 1

Step 3: Diuretic Therapy

Given the elevated BNP of 505 pg/mL indicating volume overload:

• Initiate loop diuretic (furosemide 20-40 mg daily, adjusting based on symptoms and volume status)
• Titrate to achieve euvolemia while monitoring renal function closely
• The goal is symptom relief; diuretics do not reduce mortality but are essential for congestion management 1

Critical Monitoring Parameters

Renal Function Management

• Accept modest creatinine increases (up to 30%) after starting ACE inhibitors or MRAs as this represents hemodynamic changes and does not negate the mortality benefit 4
• If creatinine rises >30% or eGFR drops below 30: hold MRA, reduce ACE inhibitor dose, and consider nephrology referral
• Do not discontinue life-saving therapies prematurely for small changes in renal biomarkers 4

Hyperkalemia Management

• Target potassium <5.0 mEq/L for optimal GDMT dosing
• If potassium 5.0-5.5 mEq/L: reduce MRA dose, dietary counseling, consider potassium binders
• If potassium >5.5 mEq/L: hold MRA temporarily, address contributing factors
• Hyperkalemia should not be a reason to avoid GDMT entirely; use potassium binders if needed to enable therapy 4

Hypotension Considerations

• Systolic BP 90-100 mmHg is acceptable if asymptomatic
• If symptomatic hypotension occurs: reduce or eliminate non-GDMT vasodilators first, then adjust GDMT doses while maintaining all four classes if possible 5, 6

Titration Strategy

Uptitrate all medications to target or maximally tolerated doses over 6-12 weeks 2. The sequence can be guided by clinical factors, but all four foundational classes should be initiated early, ideally before hospital discharge if this is a new diagnosis 2.

Common Pitfall to Avoid

Do not delay initiation of one drug class while waiting to reach target doses of another. The evidence supports simultaneous or rapid sequential initiation 2. The combination of all four classes at lower doses is superior to high-dose monotherapy or dual therapy 7.

Special Consideration for This Patient

With eGFR 42, this patient is at the threshold where medication management becomes more complex. Referral to a heart failure specialist should be considered if you encounter difficulty balancing renal function, hyperkalemia, and GDMT optimization 1. However, this should not delay initiation of therapy—start the medications and refer concurrently if needed.

The elevated BNP (505 pg/mL) in the context of reduced kidney function still carries significant prognostic weight and should not be dismissed as "just from kidney disease" 8. This level predicts higher absolute risk of adverse outcomes and reinforces the urgency of aggressive GDMT implementation.